Home/Biosimilar Atlas/Rituximab/Biocad rituximab

Biocad rituximab

Rituximab biosimilar developed by Biocad, development code BCD-020. Reference product MabThera (Rituxan in the United States).

Brands by market: Brand not published by CDSCO (India, import) ยท Commercial partner or holder: Biocad India (import)
FDAnot listed
EMAnot listed
CDSCOJul 2017permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Biocad India Pvt Ltd
Pathway
Import and marketing permission
Approved
Jul 2017
Application or permission
Import permission
Indications as licensed
NHL, RA, CLL, GPA and MPA
Presentations
100 mg and 500 mg vials
Source
S013
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All rituximab biosimilars

Planning rituximab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.